Clinical trials: sponsored by OHSU Knight Cancer Institute
Breast Cancer, Cancer Survivor
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
RATIONALE: Aerobic exercise, resistance exercise, and flexibility and relaxation training may reduce fatigue and improve the health and quality of life of breast cancer survivors.
- Conditions
- Breast Cancer, Cancer Survivor, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults
- Trial name
- NCT00662103
- Testing
- exercise intervention, laboratory biomarker analysis, questionnaire administration
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Neoplasm, Osteoporosis, Postmenopausal
Optimizing Body Composition & Health After Breast Cancer
The purpose of this study is to conduct a 12-month randomized controlled trial comparing the effects of strength training exercise to stretching and relaxation exercise (control) on body composition (bone, muscle and fat mass)…
- Trial name
- NCT00659906
- Testing
- Resistance Exercise, Flexibility Training
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Neoplasm, Osteoporosis, Postmenopausal
Strength Training for Older Breast Cancer Survivors
Women aged 50 and older are disproportionately affected by breast cancer, not only in terms of new diagnoses, but also in terms of survivorship.
- Trial name
- NCT00591747
- Testing
- Resistance Exercise, Flexibility Training
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Cervical Cancer
CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
The goal of this project is to develop and pilot test an innovative approach for overcoming barriers to cancer screening among women with physical disabilities (WWD) in rural Oregon.
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01773980
- Testing
- Clinic Intervention, Patient Intervention
- Where
- United States
- Volunteers
- 1,570 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
RATIONALE: Calcitriol may cause pancreatic cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00238199
- Testing
- calcitriol, docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Thyroid Cancer
Molecular Markers in Thyroid Cancer
The purpose of this study is to evaluate how common gene mutations are in benign and malignant thyroid lesions.
- Trial name
- NCT00598364
- Where
- United States
- Volunteers
- 847 people
- Sponsor
- OHSU Knight Cancer Institute
Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
This phase I/II trial studies the side effects and best dose of linsitinib when given together with erlotinib hydrochloride and radiation therapy after surgery in treating patients with advanced or recurrent head and neck cancer.
- Conditions
- Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01465815
- Testing
- erlotinib hydrochloride, linsitinib, radiation therapy
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Colorectal Cancer
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer.
- Trial name
- NCT00642746
- Testing
- Erlotinib, Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with relapsed diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), or mantle cell lymphoma (MCL).
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Trial name
- NCT01397591
- Testing
- Ofatumumab, Bortezomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
Compassionate Use Ponatinib
The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias.
- Trial name
- NCT01549548
- Testing
- Ponatinib
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the tumor cells.
- Trial name
- NCT00516542
- Testing
- letrozole, DHEA, pharmacological study
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00242931
- Testing
- Nonmyeloablative stem cell conditioning regimen
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Myelodysplastic Syndromes
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253513
- Testing
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide and bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00244920
- Testing
- bicalutamide, leuprolide acetate, squalamine lactate
- Sponsor
- OHSU Knight Cancer Institute
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227682
- Testing
- ascorbic acid, arsenic trioxide, dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Menopausal Symptoms
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
RATIONALE: Raloxifene and exercise may improve bone health and quality of life in breast cancer survivors. Assessing bone health and quality of life may improve the ability to plan treatment.
- Conditions
- Breast Cancer, Menopausal Symptoms, Osteoporosis
- Trial name
- NCT00031811
- Testing
- raloxifene, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell…
- Trial name
- NCT00053248
- Testing
- arsenic trioxide, imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute